RT Journal Article
SR Electronic
T1 Late Breaking Abstract - Effects of a new airway clearance technology in children with cystic fibrosis - A homecare randomized controlled trial
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3379
DO 10.1183/13993003.congress-2021.PA3379
VO 58
IS suppl 65
A1 Katarzyna Walicka-Serzysko
A1 Magdalena Postek
A1 Justyna Milczewska
A1 Natalia Jeneralska
A1 Aleksandra Cichocka
A1 Ewa Siedlecka
A1 Laurent Morin
A1 Dorotha Sands
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3379.abstract
AB Introduction: This trial aims to evaluate in children the effects of a new airway clearance technology (Simeox, Physio-Assist) added to optimal standard care (SC) including chest physiotherapy (CPT) at home.Methods: 40 pediatric patients (8-17 years) with clinically stable CF were randomized 1:1 in a cross-over trial: SC with (device) or without (control) Simeox. All patients performed CPT x3/day + bronchodilators x2/day and were treated x2/day with Simeox in device group. After 1 month of therapy at home, patients switched on other study group for 1 additional month of therapy. Spirometry, body plethysmography (BP), Impulse oscillometry system (IOS), Lung Clearance Index (LCI), health-related quality of life (CFQ-R), side effects, tolerability, satisfaction were assessed during the study.Results: Baseline data: F/M 22/18, 13±3 y, BMI 19±3 kg/cm2, FEV1 91±18%, FVC 97±14%. No side effects occurred. IOS parameters did not change in both groups. Compared to baseline, LCI z-score remained stable in device group but worsened in control group (p=0.014). MEF75 z-score improved in device group versus control (+0.30, p=0.008), other spirometry and BP criteria did not change in both groups. Physical functioning domain score of CFQ-R was improved in device group only (+3.4 versus control, p=0.015), respiratory score was unchanged in both groups. No pain nor discomfort in 95% of patients, 78% felt no fatigue during session. 73% preferred Simeox to CPT and 95% recommended it to other patients.Conclusions: These results suggest that Simeox may improve drainage of central and peripheral airways in children with clinically stable CF and could be an option in chronic treatment of CF.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3379.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).